Home Healthcare Biotechnology Oncolytic Virus Therapies Market

Oncolytic Virus Therapies Market Size, Share & Trends Analysis Report By Commercialized Therapies (Imlygic, Oncorine, RIGVIR), By Pipeline Therapies (Phase I, Phase II, Phase III, Phase IV), By Type of Virus (Genetically Engineered Oncolytic Virus, Reovirus (Respiratory Enteric Orphan Virus)), By Application (Solid Tumor, Hematological Malignancies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR3480DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Oncolytic Virus Therapies Market, By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
    1. Imlygic
    2. Oncorine
    3. RIGVIR
  2. Oncolytic Virus Therapies Market, By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
    1. Phase I
    2. Phase II
    3. Phase III
    4. Phase IV
  3. Oncolytic Virus Therapies Market, By Type of Virus 2022-2034 (USD MILLION/ Units)
    1. Genetically Engineered Oncolytic Virus
      1. Herpes Simplex Virus (HSV)
      2. Adenovirus
      3. Vaccinia Virus
      4. Oncolytic Wild-Type Virus
    2. Reovirus (Respiratory Enteric Orphan Virus)
      1. Newcastle Disease Virus (NDV)
      2. Vesicolar Stomatitis Virus (VSV)
  4. Oncolytic Virus Therapies Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Solid Tumor
      1. Breast Cancer
      2. Prostate Cancer
      3. Lung Cancer
      4. Glioblastoma
      5. Melanoma
      6. Other Applications
    2. Hematological Malignancies
      1. Lymphoma
      2. Leukemia
      3. Myeloma
  5. Regional Oncolytic Virus Therapies Market
    1. North America
      1. North America Oncolytic Virus Therapies Market By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      2. North America Oncolytic Virus Therapies Market By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      3. North America Oncolytic Virus Therapies Market By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      4. North America Oncolytic Virus Therapies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      5. U.S.
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      6. Canada
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    2. Europe
      1. Europe Oncolytic Virus Therapies Market By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      2. Europe Oncolytic Virus Therapies Market By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      3. Europe Oncolytic Virus Therapies Market By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      4. Europe Oncolytic Virus Therapies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      5. U.K.
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      6. Germany
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      7. France
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      8. Spain
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      9. Italy
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      10. Russia
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      11. Nordic
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      12. Benelux
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      13. Rest of Europe
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    3. APAC
      1. APAC Oncolytic Virus Therapies Market By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      2. APAC Oncolytic Virus Therapies Market By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      3. APAC Oncolytic Virus Therapies Market By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      4. APAC Oncolytic Virus Therapies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      5. China
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      6. Korea
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      7. Japan
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      8. India
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      9. Australia
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      10. Taiwan
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      11. South East Asia
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      12. Rest of Asia-Pacific
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    4. Middle East and Africa
      1. Middle East and Africa Oncolytic Virus Therapies Market By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      2. Middle East and Africa Oncolytic Virus Therapies Market By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      3. Middle East and Africa Oncolytic Virus Therapies Market By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      4. Middle East and Africa Oncolytic Virus Therapies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      5. UAE
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      6. Turkey
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      7. Saudi Arabia
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      8. South Africa
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      9. Egypt
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      10. Nigeria
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      11. Rest of MEA
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    5. LATAM
      1. LATAM Oncolytic Virus Therapies Market By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      2. LATAM Oncolytic Virus Therapies Market By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      3. LATAM Oncolytic Virus Therapies Market By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      4. LATAM Oncolytic Virus Therapies Market By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      5. Brazil
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      6. Mexico
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      7. Argentina
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      8. Chile
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      9. Colombia
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
      10. Rest of LATAM
        1. Imlygic
        2. Oncorine
        3. RIGVIR
        4. Phase I
        5. Phase II
        6. Phase III
        7. Phase IV
        8. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        9. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
        10. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        11. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.